Ipsen says Phase III BOLD trial of Bylvay in biliary atresia missed primary endpoint

The 254-patient study tested odevixibat against placebo after Kasai surgery, with native liver survival at week 104 as the main measure.

Summary

verifying reliability

Terms & Concepts

No specialized terms available for this topic.